Sérgio B. Sousa

Sérgio B. Sousa

Auto-generated profile, based on publicly available information

Sérgio B. Sousa

Hospital Pediátrico de Coímbra, Unidade Local de Saúde de Coímbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
OSOliver Semler
Oliver Semler
VCValérie Cormier-Daire
Valérie Cormier-Daire
ELEkkehart Lausch
Ekkehart Lausch
MBMichael B. Bober
Michael B. Bober
RCRicki Carroll
Ricki Carroll
JHJulie H Hoover-Fong
Julie H Hoover-Fong
Introduction Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical guidance for the real-world use of vosoritide. Methods Two meetings were held to gather insight and early experience from experts in Europe, the Middle East, and the USA. The group comprised geneticists, pediatric endocrinologists, pediatricians, and orthopedic surgeons. Current practices and considerations for vosoritide were discussed, including administration practicalities, assessments, and how to manage expectations. Results A crucial step in the management of achondroplasia is to determine if adequate multidisciplinary support is in place. Training for families is essential, including practical information on administration of vosoritide, and how to recognize and manage injection-site reactions. Advocated techniques include establishing a routine, empowering patients by allowing them to choose injection sites, and managing pain. Patients may discontinue vosoritide if they cannot tolerate daily injections or are invited to participate in a clinical trial. Clinicians in Europe and the Middle East emphasized the importance of assessing adherence to daily injections, as non-adherence may impact response and reimbursement. Protocols for monitoring patients receiving vosoritide may be influenced by regional differences in reimbursement and healthcare systems. Core assessments may include pubertal staging, anthropometry, radiography to confirm open physes, the review of adverse events, and discussion of concomitant or new medications—but timing of these assessments may also differ regionally and vary across institutions. Patients and families should be informed that response to vosoritide can vary in both magnitude and timing. Keeping families informed regarding vosoritide clinical trial data is encouraged. Conclusion The early real-world experience with vosoritide is generally positive. Sharing these insights is important to increase understanding of the practicalities of treatment with vosoritide in the clinical setting.

5 February 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JHJulie H Hoover-Fong
Julie H Hoover-Fong
OSOliver Semler
Oliver Semler
BBBobbie Barron
Bobbie Barron
Paulo Ferrez Collett-SolbergPaulo Ferrez Collett-Solberg
Paulo Ferrez Collett-Solberg
EFEllen Fung
Ellen Fung
KMKlaus Mohnike
Klaus Mohnike
In the clinical care of people with disproportionate short stature, healthcare practitioners need to accurately collect anthropometric measurements over time, including height, weight, head circumference, and lengths of affected limb and body segments. Accurate anthropometric measurements are important for diagnostic evaluation, tracking growth, measuring response to pharmacologic therapies or surgeries, and monitoring for potential complications. However, for this clinical population, anthropometric measurements may need to be adjusted or modified to accommodate characteristics such as body disproportions, joint contractures, long bone deformities, spinal deformities, or muscle hypotonia. This article provides guidance for key anthropometric measurements in children and adults with disproportionate short stature, with a focus on people with achondroplasia. The measurements described in this article and illustrated in the infographics can be performed without expensive specialized equipment and are suitable for a variety of clinical settings.

5 June 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
IRInês B. Rua
Inês B. Rua
ISIsabel Silva
Isabel Silva
CBChristoph Beger
Christoph Beger
CGCristina Gomes
Cristina Gomes
MPMaria J. Pais
Maria J. Pais
SSSérgio B. Sousa
Sérgio B. Sousa
Introduction Achondroplasia, the most common skeletal dysplasia, is caused by autosomal dominant gain-of-function pathogenic variants in the fibroblast growth factor receptor 3 (FGFR3) gene. Vosoritide, a C-type natriuretic peptide analog, is a first-in-class targeted treatment for achondroplasia that counteracts overactive FGFR3 signaling to stimulate endochondral bone growth. This retrospective cohort study evaluated growth, safety, and treatment compliance in children with achondroplasia receiving vosoritide under an early access program in Portugal. Methods Twenty-seven children aged 2–14 years with a genetically confirmed diagnosis of achondroplasia were treated with vosoritide at a single Portuguese center for at least 6 months between January 2022 and June 2024. The analysis included children with severe achondroplasia-associated complications. Anthropometric measurements collected to characterize the effect of vosoritide on growth included height standard deviation score (SDS) and annualized growth velocity (AGV). Student’s t test was used for statistical comparisons. Safety and tolerability endpoints included adverse drug reactions and treatment adherence. Results In total, 15 children completed at least 24 months of treatment. After 24 months of treatment, mean variation in height SDS increased from baseline by + 0.95 SD (P ≤ 0.0001), referenced to an untreated achondroplasia-specific population, and + 0.56 SD (P ≤ 0.0001) relative to children of average stature. Additionally, mean AGV from baseline was 5.87 cm/year (95% confidence interval 5.14–6.60), resulting in a significant increase of + 1.62 cm/year (P ≤ 0.0001). Injection site reactions were the most common adverse drug reaction observed (n = 14); no serious adverse drug reactions were reported. There were no discontinuations due to adverse drug reactions. Conclusion Vosoritide showed long-term effectiveness in a real-world Portuguese population of patients with achondroplasia. Vosoritide was also well tolerated, and patients showed good adherence to treatment. These findings were consistent with the outcomes of clinical trials and existing real-world experience.

15 May 2024 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
SFSvein Fredwall
Svein Fredwall
MAMoeenaldeen AlSayed
Moeenaldeen AlSayed
TBTawfeg Ben-Omran
Tawfeg Ben-Omran
SBSilvio Boero
Silvio Boero
VCValérie Cormier-Daire
Valérie Cormier-Daire
MIMelita Irving
Melita Irving
Achondroplasia is a lifelong condition requiring lifelong management. There is consensus that infants and children with achondroplasia should be managed by a multidisciplinary team experienced in the condition. However, many people are lost to follow-up after the transition from paediatric to adult care, and there is no standardised approach for management in adults, despite the recent availability of international consensus guidelines. To address this, the European Achondroplasia Forum has developed a patient-held checklist to support adults with achondroplasia in managing their health. The checklist highlights key symptoms of spinal stenosis and obstructive sleep apnoea, both among the most frequent and potentially severe medical complications in adults with achondroplasia. The checklist acts as a framework to support individuals and their primary care provider in completing a routine review. General advice on issues such as blood pressure, pain, hearing, weight, adaptive aids, and psychosocial aspects are also included. The checklist provides key symptoms to be aware of, in addition to action points so that people can approach their primary care provider and be directed to the appropriate specialist, if needed. Additionally, the European Achondroplasia Forum offers some ideas on implementing the checklist during the transition from paediatric to adult care, thus ensuring the existing multidisciplinary team model in place during childhood can support in engaging individuals and empowering them to take responsibility for their own care as they move into adulthood.

15 May 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
BFBrigitte Fauroux
Brigitte Fauroux
MAMoeenaldeen AlSayed
Moeenaldeen AlSayed
TBTawfeg Ben-Omran
Tawfeg Ben-Omran
SBSilvio Boero
Silvio Boero
MBMieke Boon
Mieke Boon
SSSérgio B. Sousa
Sérgio B. Sousa
Due to the craniofacial anatomy of people with achondroplasia, sleep-disordered breathing (SDB) occurs more frequently than in the average stature population. SDB, which comprises obstructive sleep apnoea (OSA), more rarely central sleep apnoea (CSA), and nocturnal alveolar hypoventilation (NH), may present at any age in patients with achondroplasia. Untreated SDB is associated with neurocognitive dysfunction, cardiovascular, and metabolic complications in children and adults. There continues to be debate on the optimal assessment and management of SDB in achondroplasia. To help address this, the European Achondroplasia Forum (EAF), a network of clinicians and patient advocates representative of the achondroplasia clinical community, organised a virtual workshop in October 2023 to scrutinise, vote and agree upon five guiding principles for managing SDB in achondroplasia. This workshop was attended by 40 healthcare professionals, including clinical geneticists, general practitioners and consultants, orthodontic and orthopaedic surgeons, paediatricians, paediatric endocrinologists and pulmonologists, sleep researchers and specialists, and two patient advocacy group representatives. The five guiding principles focus on lifelong assessment and proactive management, incorporating individualised sleep studies, screening, and a stepwise approach to therapeutic management. The EAF was in favour of all guiding principles, with all achieving 100% consensus with high levels of agreement (range 8.9–9.7/10). In developing guiding principles for the management of SDB in achondroplasia, the EAF aims to facilitate optimal screening and management of SDB in infants, young children, and adults with achondroplasia.

12 May 2022 in Rheumatology
Verified
Journal Article
Closed access
AMAna Isabel Maduro
Ana Isabel Maduro
ASAndré Pinto Saraiva
André Pinto Saraiva
OROrlando Pimenta Rodrigues
Orlando Pimenta Rodrigues
MMMarta Marques
Marta Marques
SSSérgio B. Sousa
Sérgio B. Sousa
Sara SerraSara Serra
Sara Serra